<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053507</url>
  </required_header>
  <id_info>
    <org_study_id>114126</org_study_id>
    <nct_id>NCT01053507</nct_id>
  </id_info>
  <brief_title>Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction</brief_title>
  <official_title>Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of Treximet when taken for post traumatic headache&#xD;
      by measuring any change in the number of headache days or any change in a subject's ability&#xD;
      to think following treatment with study medication. Eligible subjects will complete 3 visits.&#xD;
      Following Visit 1, subjects will treat with their usual medication and document headache&#xD;
      symptoms and therapy in a Headache Diary. After 30 days, subjects will return for Visit 2 and&#xD;
      be randomized (like the flip of a coin) to receive Treximet or matching placebo to treat at&#xD;
      the same time each day. Treximet will be provided to treat any headache that occurs. Subjects&#xD;
      will complete a daily Diary. After 30 days, subjects will exit the study at Visit 3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled at 3 investigative sites. At Visit 1, a medical, headache, and&#xD;
      medication history will be collected and a physical and neurological exam with vital signs&#xD;
      will be performed. An ECG will be completed if one has not been completed in the previous 6&#xD;
      months. Subjects will be administered a series of psychological tests to help the study&#xD;
      doctor decide whether or not a subject is eligible. The Headache Impact Test-6 and Migraine&#xD;
      Specific Quality of Life Questionnaire will be completed at each visit. During a 30-day&#xD;
      Baseline Period, subjects will treat with their usual medication and complete a daily Diary&#xD;
      documenting headache symptoms and treatment. At Visits 2 and 3 subjects will complete the&#xD;
      Mental Efficiency Workload Test and Migraine Early Warning Tool. Following randomization at&#xD;
      Visit 2, subjects will treat daily for 30 days with Treximet or a matching placebo. Subjects&#xD;
      will be provided with Treximet for rescue of any persisting or recurring headache. During the&#xD;
      Treatment Period, subjects will complete a daily Diary reporting headache symptoms and&#xD;
      response to treatment. After the 30-day Treatment Period, subjects will exit the study at&#xD;
      Visit 3 .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment rate was slower than anticipated.&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Days</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>Change in number of headache days at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Associated Headache Symptoms</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>Change in number of associated headache symptoms at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. Associated headache symptoms measured included number of incidences of: sleeplessness, difficulty thinking, and bodily pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mental Efficiency Workload Test (MEWT) Performance Index</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>The Mental Efficiency Workload Test (MEWT) performance index is a scale with minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test-6 (HIT-6) Score</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>The Headache Impact Test-6 (HIT-6) scale measures the impact of headache symptoms on subject's life. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Specific Quality of Life Questionnaire (MSQ)</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each subscale range from a 0 to 100 scale such that higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Treximet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sumatriptan/naproxen sodium</intervention_name>
    <description>Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
    <arm_group_label>Treximet</arm_group_label>
    <other_name>Treximet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject&#xD;
&#xD;
          -  is male or female between the ages of 18-65. A female is eligible to enter and&#xD;
             participate in this study if she is of: a.non-childbearing potential (i.e.,&#xD;
             physiologically incapable of becoming pregnant); or,b. child-bearing potential, has a&#xD;
             negative pregnancy test (urine or serum) at Visit 2, and agrees to one of the&#xD;
             following: Complete abstinence from intercourse from 2 weeks prior to administration&#xD;
             of the investigational product, throughout the study, and for a time interval (5 days)&#xD;
             after completion or premature discontinuation from the study to account for&#xD;
             elimination of the investigational drug; subjects utilizing this method must agree to&#xD;
             use an alternate method of contraception if they should become sexually active and&#xD;
             will be queried on whether they have been abstinent when they present to the clinic&#xD;
             for the final visit or, Female sterilization; or, Sterilization of male partner; or,&#xD;
             Implants of levonorgestrel; or, Injectable progestogen; or, Oral contraceptive&#xD;
             (combined or progestogen only); or, Any intrauterine device (IUD) with published data&#xD;
             showing that the highest expected failure rate is less than 1% per year (not all IUDs&#xD;
             meet this criterion); or, Spermicide plus a mechanical barrier (e.g., spermicide plus&#xD;
             a male condom or a female diaphragm); or, Any other barrier methods (only if used in&#xD;
             combination with any of the above acceptable methods); or, Any other methods with&#xD;
             published data showing that the highest expected failure rate for that method is less&#xD;
             than 1% per year.&#xD;
&#xD;
          -  is formally diagnosed with International Classification of Headache Disorders (ICHD)&#xD;
             5.2.2 chronic post traumatic headache&#xD;
&#xD;
          -  has &gt;15 headache days per month in past 3 months&#xD;
&#xD;
          -  has headache that, if left untreated, would have at least 1 symptom of migraine&#xD;
             (nausea, vomiting, photophobia, or phonophobia) or respond to a triptan or&#xD;
             ergotamine-containing medication with at least 50% of headaches&#xD;
&#xD;
          -  is medically stable as determined by the Investigator&#xD;
&#xD;
          -  if taking a headache preventive medication, has been on a stabilized dosage for at&#xD;
             least 30 days prior to screening.&#xD;
&#xD;
          -  if taking any concomitant medications, is on a stabilized dosage at the discretion of&#xD;
             the investigator&#xD;
&#xD;
          -  has chronic headache history only after the traumatic brain injury (TBI)&#xD;
&#xD;
          -  is able to understand and communicate intelligibly with the study observer&#xD;
&#xD;
          -  is able to take oral medication, adhere to the medication regimens and perform study&#xD;
             procedures&#xD;
&#xD;
          -  is able to read and comprehend written instructions and be willing to complete all&#xD;
             procedures and assessments required by this protocol&#xD;
&#xD;
          -  is able to demonstrate the willingness to participate by signing and understanding an&#xD;
             informed consent after full explanation of the study&#xD;
&#xD;
          -  has self-reported cognitive inefficiency or &quot;brain-fog&quot; during headache&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subject&#xD;
&#xD;
          -  has a history of serotonin syndrome&#xD;
&#xD;
          -  has any medical condition that, in the opinion of the investigator, could alter the&#xD;
             response to study medication or confound the results of the study&#xD;
&#xD;
          -  is female of childbearing potential not using adequate contraceptive measures&#xD;
&#xD;
          -  has history of retinal, basilar or hemiplegic migraine, cluster headache, or secondary&#xD;
             headaches (such as due to infection, alterations of homeostasis, ear nose and throat&#xD;
             (ENT) or psychiatric disorders, cranial or cervical disorders or neuralgias)&#xD;
&#xD;
          -  in the investigator's opinion, is likely to have unrecognized cardiovascular or&#xD;
             cerebrovascular disease (based on history or the presence of risk factors including&#xD;
             but not limited to, hypertension, hypercholesterolemia, smoker, obesity, diabetes, or&#xD;
             family history of coronary artery disease)&#xD;
&#xD;
          -  has blood pressure â‰¥140/90 millimeters of mercury (mmHg) in 2 out of 3 BP measurements&#xD;
             at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or&#xD;
             angiotensin receptor blocker&#xD;
&#xD;
          -  has a history of significant congenital heart disease, cardiac arrhythmias requiring&#xD;
             medication, or a history of a clinically significant electrocardiogram abnormality&#xD;
             that, in the investigator's opinion, contraindicates participation in this study&#xD;
&#xD;
          -  has evidence or history of any ischemic vascular diseases including: ischemic heart&#xD;
             disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's&#xD;
             Syndrome, or signs/symptoms consistent with any of the above&#xD;
&#xD;
          -  has evidence or history of central nervous system pathology including stroke and/or&#xD;
             transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower&#xD;
             the convulsive threshold; or has been treated with an antiepileptic drug for seizure&#xD;
             control within 5 years prior to screening&#xD;
&#xD;
          -  has a history of impaired hepatic or renal function that, in the investigator's&#xD;
             opinion, contraindicates participation in this study&#xD;
&#xD;
          -  has hypersensitivity, intolerance, or contraindication to the use of any triptan,&#xD;
             nonsteroidal antiinflammatory drug (NSAID) or aspirin (including all sumatriptan and&#xD;
             naproxen preparations) or has nasal polyps and asthma&#xD;
&#xD;
          -  is currently taking, or has taken in the previous three months, a migraine&#xD;
             prophylactic medication containing methysergide; or is taking a migraine or menstrual&#xD;
             migraine prophylactic medication that is not stabilized (i.e. start or change of dose&#xD;
             within 30 days prior to screening)&#xD;
&#xD;
          -  has a recent history of regular use of opioids or barbiturates for treatment of their&#xD;
             migraine headache and/or other non-migraine pain or any medication overuse that in the&#xD;
             opinion of the investigator has exacerbated or contributed to the current headache&#xD;
             pattern of the subject.&#xD;
&#xD;
          -  has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal&#xD;
             preparations containing St. John's Wort (Hypericum perforatum), anytime within the 2&#xD;
             weeks prior to screening through 2 weeks post final study treatment.&#xD;
&#xD;
          -  has history of any bleeding disorder or is currently taking any anti-coagulant or any&#xD;
             antiplatelet agent.&#xD;
&#xD;
          -  has evidence or history of any gastrointestinal surgery or GI ulceration or&#xD;
             perforation in the past six months, gastrointestinal bleeding in the past year; or&#xD;
             evidence or history of inflammatory bowel disease&#xD;
&#xD;
          -  is pregnant, actively trying to become pregnant, or breast feeding&#xD;
&#xD;
          -  has evidence of alcohol or substance abuse within the last year or any concurrent&#xD;
             medical or psychiatric condition which, in the investigator's judgment, will likely&#xD;
             interfere with the study conduct, subject cooperation, or evaluation and&#xD;
             interpretation of the study results, or which otherwise contraindicates participation&#xD;
             in this clinical trial.&#xD;
&#xD;
          -  has participated in an investigational drug trial within the previous four weeks or&#xD;
             plans to participate in another study at any time during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Neuroscience Group, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital and Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baandrup L, Jensen R. Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia. 2005 Feb;25(2):132-8. Erratum in: Cephalalgia. 2005 Mar;25(3):240.</citation>
    <PMID>15658950</PMID>
  </reference>
  <reference>
    <citation>Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.</citation>
    <PMID>14979299</PMID>
  </reference>
  <reference>
    <citation>Cady R, Farmer K. Soft tissue injuries: diagnosis and treatment. Posttraumatic headache. In Windsor R, Lox D (eds.) Hanley and Belfus, Inc. Philadelphia, PA. 207-224.</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <results_first_submitted>January 28, 2014</results_first_submitted>
  <results_first_submitted_qc>January 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2014</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Post-traumatic headache</keyword>
  <keyword>Brain injury</keyword>
  <keyword>Cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treximet</title>
          <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treximet</title>
          <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.36" spread="9.83"/>
                    <measurement group_id="B2" value="35.83" spread="12.01"/>
                    <measurement group_id="B3" value="38.48" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Days</title>
        <description>Change in number of headache days at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days</title>
          <description>Change in number of headache days at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm.</description>
          <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="7.6"/>
                    <measurement group_id="O2" value="-0.30" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Associated Headache Symptoms</title>
        <description>Change in number of associated headache symptoms at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. Associated headache symptoms measured included number of incidences of: sleeplessness, difficulty thinking, and bodily pain.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Associated Headache Symptoms</title>
          <description>Change in number of associated headache symptoms at Day 0 vs. Day 30 in Treximet arm vs. Placebo arm. Associated headache symptoms measured included number of incidences of: sleeplessness, difficulty thinking, and bodily pain.</description>
          <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
          <units>change in number of symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Sleeplessness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="7.76"/>
                    <measurement group_id="O2" value="-2.30" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Difficulty Thinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="12.32"/>
                    <measurement group_id="O2" value="0.00" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="6.52"/>
                    <measurement group_id="O2" value="-3.80" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mental Efficiency Workload Test (MEWT) Performance Index</title>
        <description>The Mental Efficiency Workload Test (MEWT) performance index is a scale with minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mental Efficiency Workload Test (MEWT) Performance Index</title>
          <description>The Mental Efficiency Workload Test (MEWT) performance index is a scale with minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning.</description>
          <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="2.28"/>
                    <measurement group_id="O2" value="3.4" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="2.23"/>
                    <measurement group_id="O2" value="3.11" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Impact Test-6 (HIT-6) Score</title>
        <description>The Headache Impact Test-6 (HIT-6) scale measures the impact of headache symptoms on subject's life. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Impact Test-6 (HIT-6) Score</title>
          <description>The Headache Impact Test-6 (HIT-6) scale measures the impact of headache symptoms on subject's life. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
          <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.43" spread="6.65"/>
                    <measurement group_id="O2" value="61.91" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.57" spread="6.13"/>
                    <measurement group_id="O2" value="61.91" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Migraine Specific Quality of Life Questionnaire (MSQ)</title>
        <description>The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each subscale range from a 0 to 100 scale such that higher scores indicate better quality of life.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Specific Quality of Life Questionnaire (MSQ)</title>
          <description>The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each subscale range from a 0 to 100 scale such that higher scores indicate better quality of life.</description>
          <population>Analysis population only includes subjects that provided data at both time points (Day 0 and Day 30).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - Role Function-Restrictive Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="12.34"/>
                    <measurement group_id="O2" value="45.71" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - Role Function-Restrictive Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.59" spread="23.81"/>
                    <measurement group_id="O2" value="50.39" spread="19.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - Role Function-Preventive Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.29" spread="14.84"/>
                    <measurement group_id="O2" value="68.64" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - Role Function-Preventive Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="13.84"/>
                    <measurement group_id="O2" value="69.55" spread="24.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - Emotional Function Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="18.05"/>
                    <measurement group_id="O2" value="50.91" spread="25.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - Emotional Function Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.03" spread="28.76"/>
                    <measurement group_id="O2" value="57.58" spread="29.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0, Day +30</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treximet</title>
          <description>In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.&#xD;
sumatriptan/naproxen sodium: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.&#xD;
Placebo: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Heart Rate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Head Burning Sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Shaking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Increased Energy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thirsty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Excessive Sweating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Slow Motor Function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Jaw Ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth Ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Left Arm Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Left Scapula Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Left Leg Fell Asleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Right Arm Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aching Leg Muscles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sensations of Needles in Head</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cramping Sides</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Calf Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Temporal Bilateral Vein Throbbing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Light Sensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Moody</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Head Cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger K. Cady</name_or_title>
      <organization>Clinvest/A Division of Banyan Group, Inc.</organization>
      <phone>417-841-3673</phone>
      <email>jtarrasch@clinvest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

